William Prather, Pluristem Therapeutics
April 24, 2012
William R. Prather RPh, MD – Senior VP Corporate Development PLURISTEM THERAPEUTICS
PLURISTEM THERAPEUTICS (NasdaqCM: PSTI; TASE: PLTR) returned to NYC MedTech for an UPDATE.
Pluristem Therapeutics Inc. (NasdaqCM: PSTI; TASE: PLTR) is a leading developer of placenta-based cell therapies. The company’s patented PLX (PLacental eXpanded) cells drug delivery platform releases a cocktail of therapeutic proteins in response to a variety of local and systemic inflammatory diseases. PLX cells are grown using the company’s proprietary 3D micro-environmental technology and are an off-the-shelf product that requires no tissue matching or immune-suppression treatment prior to administration. PLX-PAD comprehensive clinical development plan has been recognized by both the EMA and FDA, targeting a sub-population of 20-million patients of Peripheral Artery Disease (PAD) market.
